DEC-C Post-Transplant
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 126 patients (estimated)
- Sponsors
- Washington University School of Medicine
- Collaborators
- Taiho Oncology, Inc.
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Minimal Residual Disease (MRD), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1513
- NCT Identifier
- NCT04742634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.